1	Unraveling the Molecular Landscape of Congenital
2	Pseudoarthrosis of the Tibia: Insights from a
3	<b>Comprehensive Analysis of 162 Probands</b>
4	Guanghui Zhu <sup>1,2,3#</sup> , Nan Li <sup>4#</sup> , Yu Zheng <sup>1,3,5#</sup> , Shunyao Wang <sup>4</sup> , Ge Yang <sup>1,2,3</sup> , Yaoxi Liu <sup>1,2,3</sup> ,
5	Zongren Xu <sup>4</sup> , Hui Huang <sup>4*</sup> , Huanhuan Peng <sup>4*</sup> , Haibo Mei <sup>1,2,3*</sup>
6	<sup>1</sup> Department of Pediatric Orthopedics, Hunan Children's Hospital, Hunan 410007, PR China
7	<sup>2</sup> Hunan Provincial Key Laboratory of Pediatric Orthopedics, Hunan 410007, PR China
8	<sup>3</sup> The school of pediatrics, University of South China, Hunan 410007, PR China
9	<sup>4</sup> BGI Genomics, BGI-Shenzhen, Shenzhen 518083, China
10	<sup>5</sup> Hunan Children's Research Institute (HCRI), Hunan Children's Hospital, Hunan 410007, PR
11	China
12	
13	
14	
15	
16	<sup>*</sup> Guanghui Zhu, Nan Li and Yu Zheng contributed equally to this article.
10	Corresponding autors:
10	hui Huang, BGI Genomics, BGI-Shenzhen, Shenzhen 518085, China. E-mail address:
20 19	Huanbuan Peng, BGI Genomics, BGI Shenzhen, Shenzhen 518083, China, E mail address:
20 21	nenghh@genomics cn:
22	Haibo Mei Hunan Key Laboratory of Pediatric Orthopedics: Department of Pediatric
23	Orthopedics. Hunan Children's Hospital: The school of pediatrics. University of South China
24	Hunan 410000, PR China E-mail address: meihaibo@sohu.com:
25	
26	Fundings: Opening fundings of Hunan Provincial Key Laboratory of Pediatric Orthopedics
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
৩/ ২০	
30 30	
40	
41	TE. This propriet reports now research that has not been certified by near review and should not be used to suids clinical meeting.
NU	The map proprint reports new research that has not been definied by peer review and should not be used to guide Childan practice.

#### 42 Abstract

Congenital pseudarthrosis of the tibia (CPT, HP:0009736), 43 commonly known as bowing of the tibia, is a rare congenital 44 tibia malformation characterized by spontaneous tibial fractures 45 and the difficulty of reunion after tibial fractures during early 46 childhood. with low prevalence between а verv 47 1/250,000~1/140,000. While 80%-84% of CPT cases present 48 with neurofibromatosis type 1, caused by the mutations in *NF1*, 49 the underlying cause of CPT is still unclear. Considering the 50 congenital nature and the low prevalence of CPT, we hypothesized 51 that the rare genomic mutations may contribute to CPT. In this 52 study, we conducted whole exome sequencing on 159 patients 53 with CPT and full-length transcriptome sequencing on an 54 additional 3 patients with CPT. The data analysis showed there 55 were 179 significantly up-regulated genes which were enriched in 56 40 biological processes among which 21 biological processes hold 57 their loss of function (LoF) excesses between 159 cases against 58 208 controls from 1000 Genomes Project. From those 21 59 biological processes with LoF excesses, there were 259 LoF-60 carried genes among which 40 genes with 56 LoF variations in 63 61 patients were enriched in osteoclast differentiation pathway 62 (hsa04380) with its 3 directly regulated pathways including 63

MAPK signaling pathway (hsa04010), calcium signaling pathway 64 (hsa04020) and PI3K-Akt signaling pathway (hsa04151), as well 65 as fluid shear stress and atherosclerosis pathway (hsa05418) 66 while 12 patients carried 9 LoF variations in the NF1 gene. The 67 rare LoF variations in these pathways accounted for  $\sim 39.6\%$  of 68 this CPT cohort. These findings shed light on the novel genetic 69 mutations and molecular pathways involved in CPT, providing a 70 new framework for understanding how the genetic variations 71 regulate the biological processes in the pathology of CPT and 72 indicating potential next directions to further elucidate the 73 pathogenesis of CPT. 74

#### 75 Introduction

pseudarthrosis of the tibia (CPT) is a rare Congenital 76 orthopedic disease with an incidence between 1 in 140,000 and 1 77 in 250,000 live births [1]. It is characterized by the pseudarthrosis 78 or pathological fractures of the anterolateral part of the tibia in 79 early life, resulting in bowing, narrowing of the medullary canal, 80 or the presence of a cyst. This condition poses a significant 81 surgical challenge due to recurrent fractures and the inability to 82 achieve bone union [2]. Congenital anterolateral bowing of the 83 tibia is generally considered a precursor of CPT and is commonly 84

associated with neurofibromatosis type 1(NF1), a common 85 autosomal dominant genetic disorder [3]. Previous research has 86 reported that 80%–84% of CPT cases present with NF1(NF1-CPT) 87 in the epidemiology and the genomic mutations in the NF1 gene 88 have been linked to CPT in the genomics [4-7]. The double 89 inactivation model has been proposed as a hypothesis to explain 90 these associations [8-11] . However, other researchers have 91 suggested that the molecular pathogenesis of NF1-CPT may not 92 entirely explained by second mutations or loss of be 93 heterozygosity of the NF1 gene [7, 12, 13]. 94

Recent investigations have shed light on the molecular basis 95 of CPT, for example, *NF1* gene has been reported to be involved in 96 bone remodeling and mineralization [14]. Inhibited bone 97 formation and stimulated bone resorption have also been 98 reported in patients with CPT who harbor NF1 mutations [15]. 99 Furthermore, the involvement of FGFR3 signaling in cartilage-to-100 bone transformation for bone repair [16] and the contribution of 101 vasoactive intestinal peptide through ERK and NF-κB signal 102 pathways have been implicated in CPT [17]. Differentially 103 expressed proteins (DEPs) found in serum-derived exosomes of 104 CPT patients have been shown to inhibit bone formation and 105 stimulate bone resorption[18] while DEPs from in the tibia 106

periosteum tissues are mainly involved in cell matrix assembly, 107 cell adhesion, AKT-PI3K signal pathway activation, and vascular 108 agglutination of CPT patients [19]. These conclusions indicate the 109 intricate biological processes and molecular regulation pathways 110 associated with bone homeostasis potentially contribute to CPT 111 [20-23]. However, a comprehensive understanding of the etiology 112 of CPT is still elusive due to the rarity of CPT and limited samples 113 in previous studies. 114

To address this gap, we employed an approach used to 115 investigate the severe pediatric developmental disorders with a 116 low prevalence and the complex genetic architecture, aiming to 117 identify the low-frequency gene mutations in 159 sporadic CPT 118 patients. This approach have been successful in elucidating the 119 genetic basis of other neurodevelopmental disorders, including 120 epilepsy [24-28], craniosynostosis [29-31], autism [32-40] and 121 congenital heart disease [41-46]. Specially the rare protein-122 damaging variations (PDV), particularly loss of function (LoF) 123 mutations, have been identified a main contributor to congenital 124 developmental diseases characterized by low prevalence and 125 early onset. In light of this, we hypothesized that CPT can also be 126 explained, at least partially, by the rare LoF variants with 127 incomplete penetrance. To test this hypothesis, we conducted 128

whole exome sequencing (WES) on a substantial cohort of 159
individuals affected by idiopathic CPT. Additionally, we performed
a full-length transcriptome sequencing on 3 CPT patients to
validate the reported biological processes and detect the new
ones associated with CPT.

In this study, we present our comprehensive genetic analysis, aiming to uncover the complex genetic architecture and molecular mechanism underlying CPT. Our findings have the potential to enhance the understanding of CPT pathogenesis and provide valuable guidance for the development of novel therapeutic approaches targeting the identified genetic factors.

#### 140 **Results**

To comprehensively explore the genetic basis and biological 141 processes underlying CPT, a cohort of 159 along with an 142 additional 3 Chinese Han CPT patients, with an average age of 42 143 months, were enrolled for WES and full-length transcriptome 144 sequencing respectively. In the WES, targeted bases in each 145 sample were sequenced a mean of 136 times by independent 146 reads, with 98.73% reading 20 or more times. Following variation 147 calling, a totally of 286,945 single nucleotide polymorphisms 148 (SNPs) and 27,807 insertions/deletions (InDels) were detected. 149

For the transcriptome sequencing, an average of 4,816,579 reads
with a length of 787 bp were obtained for each sample.

# 40 bone homeostasis related biological processes were up-regulated in CPT patients

To get insights into the CPT-related pathways, we performed 154 nanopore sequencing on the periosteum tissues from three CPT 155 patients against two healthy individuals. The differential 156 expression analysis of transcriptome identified 179 genes up-157 regulated and 134 down-regulated genes excluding NF1 gene 158  $(|\log FC| > 2, FDR < 0.01)$  in patients with CPT (Fig1 a and b). 159 Functional enrichment analysis of those up-regulated genes 160 uncovered 40 significantly enriched biological processes 161 These (threshold P=0.01). enriched biological processes 162 encompassed skeletal system development (logP=-11.96), tissue 163 remodeling including bone resorption, cell matrix assembly 164 (logP=-10.37) [47, 48], regulation of cell adhesion (logP=-8.44), 165 regulation of MAPK cascade [49] (logP=-5.22) and autophagy in 166 bone metabolism [50, 51], which have been associated with bone 167 formation and bone remodeling [19, 52-54]. Additional enriched 168 biological progress included ossification (e.g., bone 169 mineralization and endochondral ossification) [55], myeloid 170

leukocyte differentiation (e.g., osteoclast differentiation and 171 osteoclast development) [56, 57], epithelial cell proliferation (e.g., 172 angiogenesis) [58-61], inorganic ion homeostasis [62, 63], 173 regulation of hormone levels [64, 65], negative regulation of 174 response to external stimulus [57, 66], Vitamin D receptor 175 pathway [67-69], cell migration and chemotaxis [70] (Fig.1.c and 176 supplementary table 1, threshold P = 0.05/100 = 5e-4 by 177 Bonferroni correction). Some of these processes have been 178 reported in the DEPs of CPT patients [18, 19, 53] and also known 179 to play crucial important role in the metabolism of bone 180 homeostasis. The enriched biological processes identified in the 181 transcriptome analysis provide a comprehensive reflection of the 182 etiology of CPT. 183

## 184 21 of 40 biological processes beared the LoF excesses in 185 CPT patients

Considering the rare prevalence and early onset of CPT, we postulate that some or all of the 40 biological processes may bear a significant burden of rare LoF mutations if they contribute to CPT pathogenesis. To test this hypothesis, we analyzed the genetic burden of LoF variations from WES data. After variation calling and filtering, 1,174 confidant LoF single nucleotide variants (SNVs)

in 1,037 genes (an average of 7.38 mutations per case with a 192 mutation rate of 4.34e-9) were selected for the burden test 193 between 159 CPT cases and 208 healthy Chinese Han controls 194 from the 1000 Genomes Project. Among all the 40 significantly 195 enriched and up-regulated biological processes in transcriptome, 196 21 processes showed LoF excesses under the threshold P < 0.01197 and OR > 10 (Fig2, Table 1), indicating their potential relevance to 198 CPT. Additionally, the burden test of rare LoF mutations showed 199 no significant excess of LoF (Bonferroni corrected threshold P-200 value 0.05/1,217=4.1e-5) for each gene except for NF1 (p= 201 5.61357e-05) which was reported in the previous studies [4, 7]. 202 This result suggests that the 21 CPT-related candidate biological 203 processes, which exhibit a significant rare LoF excess, cannot be 204 detected by the burden test for single gene. Furthermore, the 205 other 19 biological processes significantly up-regulated in the 206 transcriptome and enriched in the Gene Ontology (GO) database 207 did not show a rare LoF excess, indicating that rare LoF mutations 208 alone cannot entirely explain the pathogenicity and the complex 209 genetic architecture of CPT. 210

To assess the association between the 21 biological processes and the risk of CPT, the odd ratio (OR) is used to quantify the probability LoF mutations contributing to CPT. We defined the

gene set including 5,173 genes from the 21 biological processes 214 as the transcriptome high expression (THE). The gene set of 215 biological process (GO:0008150) in GO includes 19,462 genes 216 except THE, consisting of 14,254 genes, was referred to as the 217 non-THE (NTHE). Comparing the OR of NTHE (1.73) between CPT 218 cases and controls, a substantial increase to 18.29 in THE was 219 displayed. This substantial rise in odds ratio demonstrates that 220 the rare LoF excesses from THE significantly correlated with an 221 increased risk of CPT risk. Ultimately, the specific genes 222 contributing to CPT were identified as the those overlapping 223 between the LoF-carrying genes and the THE. This resulted in the 224 discovery of 151 CPT-contributing genes. 225

## Osteoclast differentiation with its regulated pathways contributes to CPT pathogenesis

To get insight into the molecular mechanism of these 151 CPTcontributing genes, they were queried in the Kyoto Encyclopedia of Genes and Genomes (KEGG) database for the enrichment that highlighted the pathway osteoclast differentiation (hsa04380, logP=-4.83) likely plays a potential role in CPT, along with its 3 regulated pathways including MAPK signaling (hsa04010, logP=-2.99), calcium signaling (hsa04020, logP=-2.95) and PI3K-Akt

signaling (hsa04151, logP=-2.45). it was worth noting that 235 pathway(hsa05152, tuberculosis logP=-4.59), Chemical 236 carcinogenesis - DNA adducts pathway (hsa05204, logP=-4.56), 237 as well as fluid shear stress and atherosclerosis pathway 238 (hsa05418, logP=-4.57), were also identified(Fig3 a). To validate 239 these findings, we examined the LoF excesses within these 240 pathways. The results demonstrated significant LoF excesses in 241 the MAPK signaling pathway (OR = 26, P = 1.45E-9), Tuberculosis 242 pathway (OR = 12, P=1.37e-4), Chemical carcinogenesis-DNA 243 adducts pathway (OR=10, P=0.001), PI3K-Akt signaling pathway 244 (OR = 9, P = 1.48e-5), calcium signaling pathway (OR = 7, P =245 2.66e-4), and osteoclast differentiation pathway (OR = 5.5, P =246 0.001) in CPT cases (Fig3 b and Table 2). 247

Consistent with previous findings, the observed involvement 248 in the osteoclast differentiation pathway and its 3 regulated 249 pathways (MAPK signaling, calcium signaling and PI3K-Akt 250 signaling ) support the notion that CPT patients exhibit an 251 imbalance in the low reparative potential of bone tissue due to the 252 osteoclast activation prevailing over differentiation of osteoblasts, 253 progenitor and mesenchymal cells [71]. The regulation of 254 osteoclast differentiation and activation could become 255 а

promising strategy for preventing bone erosion in patients with
CPT [17].

*NF1*, a reliable CPT-causing gene reported in previous studies. 258 is believed to involve disruptions in bone remodeling and vascular 259 abnormalities. Osteoclasts in *NF1* display enhanced resorption 260 capacity and aberrant morphology [72]. The disorders of the 261 Ras/MAPK pathway have an overlapping skeletal phenotype, such 262 as scoliosis and osteopenia. The Ras proteins regulate cell 263 proliferation and differentiation. Studies have shown that 264 individuals carrying *NF1* mutations have osteoclast hyperactivity 265 and increased bone resorption in the studies [73, 74]. In our study, 266 *NF1* gene exhibits 9 LoF variations only in 12 patients (7.54%) 267 with a heterozygous genotype. Alongside AKT2, CD14, IL1RAP, 268 MAP3K4, MAP3K11, RPS6KA1, TGFA and RASGRP2, NF1 was 269 enriched in the MAPK signaling pathway (logP=-2.99). This 270 suggests a potential framework for understanding how NF1 271 contribute to the etiology of CPT. 272

Furthermore, *LILRB4*, *LILRB2*, *LILRB1* and *LILRA2* carrying 2 LoFs respectively are enriched in the osteoclast differentiation pathway along with *AKT2*, *CALCR*, *FCGR3A* and *IFNG*. The complex of *FCGR3A* and *LILRB1/LILRB2/LILRB4/LILRA2*, known as the osteoclast-associated receptor (OSCAR), is a regulator of

osteoclast differentiation and dendritic cell maturation. It has 278 been reported to cause skeleton-related phenotypes, such as 279 osteoclast differentiation, reduced osteoarthritis abnormal 280 manifestation, decreased chondrocyte apoptosis and abnormal 281 bone morphology in knockout mice [75]. In osteoclasts, OSCAR is 282 mediated by the immunoreceptor tyrosine-based activation motif 283 adaptor protein FcRy and co-stimulates osteoclasts cultured in an 284 extracellular matrix or collagen [76]. CALCR is involved in 285 regulating osteoclast-mediated bone resorption and has been 286 reported to be associated with osteoporosis and bone mineral 287 density quantitative trait locus 15 (https://www.genecards.org/). 288 IFNG suppresses osteoclastogenesis by suppressing TRAF6-289 mediated signaling downstream of RANK, the receptor for RANKL 290 [77]. That is, osteoclastogenesis would increase when the 291 expression of *IFNG* is down-regulated due to the LoF variations. 292

Additionally, *COL6A5* carrying 2 LoF mutations, accompanied by *AKT2*, *JAK3*, *NOS3*, *TGFA*, *TLR2*, *SGK2*, *PKN3*, *TNN*, *KRT16* and *OPRM1*, is enriched in PI3K-Akt signaling pathway (logP = -2.45). This pathway has been reported to be involved in CPT by quantitative proteomics analysis [19]. The knockdown of *AKT2* was reported to suppress osteoclastogenesis through the PI3K/Akt/GSK3 signaling pathway [78]. Furthermore, alongside

*HRC*, *MST1R*, *NOS3*, *P2RX1*, *TACR2*, *PPIF* and *TRDN*, *PLCZ1* carrying 300 2 LoF mutations is enriched in the calcium signaling pathway 301 (logP = -2.95). Calcium signaling plays a crucial role in osteocyte 302 mechanotransduction, as the release of calcium serves as a 303 powerful second messenger. Calcium provides essential 304 information for mechanical responses and participates in 305 downstream regulatory processes [66]. 306

Finally, GSTM4 carrying 2 LoF mutations, along with AKT2, 307 IFNG, NOS3, PLAT, SELE, ARHGEF2, GSTO1, AKR1C4, AKR1C3, PPIF 308 and *SLC26A6*, is enriched in fluid shear stress and atherosclerosis 309 (has05418). Previous studies have reported the involvement of 310 osteoclasts and osteoblasts in activating different mechanical 311 transduction pathways such as fluid shear stress and reported 312 changings in their differentiation, formation, and functional 313 mechanism induced by the application of different types of 314 mechanical stress to bone tissue[79-81]. 315

In summary, the osteoclast differentiation pathway, along with its 3 directly regulated pathways, not only exhibited rare LoF excesses but also showed shared transcriptome patterns between CPT cases and controls. These pathways serve as a reliable set of potential candidate pathways contributing to the etiology of CPT. Overall, there were 63 patients carrying 40 CPT-contributing genes with 56 LoF variations in the osteoclast differentiation
pathways and their 3 directly regulated pathways (Table 3).

# Hub genes enriched in hedgehog signaling pathway and likely regulate the molecular pathways of CPT

Interestingly, the Protein-protein interaction network analysis 326 in the 151 CPT-contributing genes indicated that there were 8 hub 327 genes (BOC, SMO, PTCH2, ULK4, CORIN, USH2A, F12 and MAGI3) 328 which showed a significant enrichment in hedgehog signaling 329 pathway (hsa04340, logP= -6.5) and 3 genes TIRAP, CD14 and 330 *TLR2* in Lipid and atherosclerosis (hsa05417, logP=-6.5). As the 331 members of Hedgehog signaling pathway, BOC, SMO and PTCH2 332 respectively carried 1 LoF mutation, and was indicated to be 333 regulated by the other 5 hub genes in the PPI network. Hedgehog 334 signaling pathway had been reported play a crucial role in 335 regulating bone formation and homeostasis[82, 83] and the 336 premature SHH signaling resulting from disruption of GPR161 337 causes defects in limb and skeletal morphogenesis[84]. 338

339 **Discussion** 

CPT is a rare bone disorder primarily affecting newborns and characterized by challenging complications such as refracture,

tibial non-union, and failed surgery [85]. The underlying 342 pathophysiology involves excessive osteoclast activity caused by 343 the fibrous hamartoma surrounding the bone and impaired 344 osteogenesis and bone morphogenetic protein function, resulting 345 in frequent tibial fractures, bone atrophy, and compromised bone 346 remodeling [86]. Neurofibromatosis type 1, with the prevalence 347 of 1/3,000 [87], is linked to CPT in many cases and contribute to 348 anterolateral bowing of the tibia, leading to pathologic 349 fracture. Previous study has claimed the gene NF1 encodes 350 neurofibromin, a ubiquitous protein expressed in osteoblasts, 351 osteoclasts, chondrocytes, fibroblasts and endothelial cells, and 352 neurofibromin negatively regulates the activity of Ras which 353 involved in cellular proliferation and differentiation, leading to 354 the physically preventing bony bridging and endochondral bone 355 repairing by the recurrent invasion and increased proliferation of 356 fibrous lesion cells in the cellular deficiencies, suggesting the role 357 of *NF1* in bone development, homeostatic regulation, and repair 358 in Neurofibromatosis type 1 [88]. However, the complete 359 understanding of CPT cannot be fully attributed to the NF1 gene 360 within the framework of neurofibromatosis type 1. And other 361 factors, including intrauterine trauma and generalized metabolic 362 disturbances at the time of birth, are believed to contribute [89]. 363

Recent studies have identified several biological processes, such as skeletal system development, tissue morphogenesis and cell differentiation/proliferation, are associated to CPT[18, 19, 53], these findings suggest the involvement of intricate molecular processes in which other genes, in cooperation with *NF1*, may contribute to CPT. However, the precise mechanisms underlying these effects have not yet been elucidated.

In this study, we sequenced the transcriptome of periosteal 371 tissues from three patients with CPT and two healthy individuals, 372 and identified 180 up-regulated genes in CPT patients, which 373 were enriched in 40 biological processes related to bone 374 homeostasis. These biological processes encompassed skeletal 375 system development, tissue remodeling (e.g., bone resorption), 376 cell matrix assembly, regulation of cell adhesion, regulation of the 377 MAPK cascade and autophagy in bone metabolism. These findings 378 are consistent with previous studies and provide an overview of 379 the biological processes likely associated with CPT, despite the 380 limited number of patient samples included in this analysis. 381 Furthermore, to gain insight into the effects of genomic LoF 382 variations on CPT, we performed WES on 159 patients and 383 observed significant excesses of rare LoF variations in 21 out of 384 the 40 biological processes. This indicates the rare LoF variations 385

play an important role in CPT-related biological processes. Most 386 importantly, through gene-pathway enrichment analysis using the 387 KEGG database, we identified 63 patients carrying 40 genes with 388 56 LoF variations in the osteoclast differentiation pathway with 389 its 3 directly regulated pathways (MAPK signaling pathway, 390 Calcium signaling pathway and PI3K-Akt signaling pathway), as 391 well as the fluid shear stress and atherosclerosis pathway. This 392 provides a comprehensive illustration of how rare genomic LoF 393 variations in the osteoclast differentiation pathways contribute to 394 the pathological process of CPT. 395

Additionally, we also observed that 19 out of the 40 biological 396 significant processes showed gene enrichment in the 397 transcriptome but did not exhibit significant LoF excesses. This 398 suggests the involvement of other types of genomic mutations 399 contributing to CPT. For instance, among the CPT patients, apart 400 from MAPK signaling pathway(P=3.67e-08), calcium signaling 401 pathway (P=1.58e-10) and PI3K-Akt signaling pathway (P=4.15e-402 10), we found missense mutations exhibited the excesses 403 specifically in apoptosis pathways (P=6.58e-05) and mTOR 404 signaling pathway (P=3.15e-05) which have been confirmed as 405 the crucial pathways orchestrating the bone resorption in bone 406 metabolic diseases [90, 91]. 407

Compared with the fact that up to 80%-84% of patients with 408 CPT present with neurofibromatosis type 1, we found NF1 carried 409 9 LoF mutations in 12 patients, with a prevalence 19% in this 410 study. This paradox in prevalence suggests some of our 56 LoF 411 mutations may not directly cause CPT but instead participated in 412 the regulation of the imbalanced bone homeostasis resulted from 413 CPT. Furtherly considering the extreme low prevalence of CPT, de 414 novo mutations would serve as more accurate genomic markers 415 for the genetic diagnosis of CPT under our current pathway 416 framework. 417

In summary, our findings highlight that rare genomic LoF variations in genes involved in osteoclast differentiation and regulation pathways play crucial role in the pathological process of CPT. This provides a new framework for understanding how genetic variations regulate biological processes in the pathology of CPT.

424

#### 425 Method

#### 426 **Patient Recruitment and study subjects**

A consecutive cohort of 165 CPT patients admitted into the
department of Orthopedics of Hunan Children's Hospital from

2016 to 2020 was enrolled in this study. For WES, a total of 159 429 CPT patients, of which 75 cases had been reported in 2019[7], 430 provided peripheral blood samples for DNA extraction and 431 sequencing. For the transcriptome sequencing, two normal 432 periosteal tissues were obtained from healthy children 433 undergoing surgery for tibial fracture, as well as three diseased 434 periosteum tissues were obtained from the patients with CPT 435 during surgery at Hunan Children's Hospital. This study had been 436 approved by the Ethics Committee of Hunan Children's Hospital, 437 and informed consent had been obtained from all patients. 438

# 439 Transcriptome sequencing by nanopore platform and 440 data analysis

#### 441 RNA Extraction from Periosteal Tissue

During the surgical procedure, periosteal tissue devoid of bone 442 needles and encompassing cortical bone was collected and 443 dissected into small fragments immediately measuring 444 approximately 200 mg with a diameter of approximately 5 mm. 445 These fragments were then placed in centrifuge tubes filled with 446 phosphate-buffered saline (PBS) and thoroughly washed. 447 Subsequently, they were transferred to cryovials and snap-frozen 448 in liquid nitrogen for storage. Total RNA extraction from the 449

periosteal tissue was performed using Takara TRIzol reagent 450 according to the manufacturer's standard protocol. The extracted 451 RNA was subjected to quality assessment using the IMPLEN Nano 452 Photometer for spectrophotometric analysis, Nanodrop 2000 for 453 concentration measurement of RNA samples, Agilent 2100 for 454 integrity assessment, and agarose gel electrophoresis. One 455 microgram of purified total RNA with a minimum RNA integrity 456 number (RIN) value of 6 was reverse transcribed into 457 complementary DNA (cDNA) using the cDNA-PCR sequencing kit 458 (SQK-PCS109). 459

460 Full-Length Transcriptome Sequencing

The experimental workflow followed the standard procedure 461 provided by Oxford Nanopore Technologies (ONT), including 462 sample quality check, library construction, library quality 463 assessment, and library sequencing. The total RNA extracted from 464 periosteal tissue was required to be at least 1.5 µg, suitable for 465 three library preparations, with a concentration of  $\geq 40$  ng/µl, a 466 volume of  $\geq 10 \mu$ l, an OD260/280 ratio between 1.7 and 2.5, an 467 OD260/230 ratio between 0.5 and 2.5, and a normal peak at 260 468 nm absorption. Samples with an RIN value of 6 or higher were 469 selected for full-length transcriptome sequencing using ONT. The 470

library construction process involved the following steps: First, 471 oligo dT primers were utilized to anneal with the polyA tail of 472 mRNA, followed by the addition of reverse transcriptase (RT) to 473 synthesize the first cDNA strand. Next, specific PCR adapters were 474 added to both ends of the first cDNA strand, and a 14-cycle cDNA 475 PCR was performed using LongAmp Tag DNA polymerase (New 476 England Biolabs, Ipswich) with an extension time of 8 minutes. 477 This step amplified the double-stranded cDNA using amplification 478 primers. Subsequently, DNA damage repair and end repair were 479 conducted using the NEBNext FFPE DNA Repair Mix and NEBNext 480 Ultra II End Repair/dA-Tailing Module to repair and end-repair 481 the nucleic acid fragments, followed by A-tailing. The sequencing 482 adapters were then ligated using the SQK-LSK110 kit (ONT), and 483 purification was carried out using Agencourt XP beads (Beckman 484 Coulter, USA). The prepared cDNA library was sequenced using 485 the Oxford Nanopore PromethION 48 platform (Biomarker, 486 Beijing). 487

After transcriptome sequencing, we trim the adaptors by software porechop v0.2.4(https://github.com/rrwick/Porechop), aligned the reads to reference hg19 and quantified gene expression using the FLAIR software [92]. We identified 179 significantly up-regulated genes and 134 significantly downregulated genes (|logFC| > 2 and FDR < 0.01) between CPT cases</li>
and controls using the differential expression analysis module of
the Trinity software [93]. Furthermore, we obtained the
significantly enriched pathways (supplementary table 1) of these
179 up-regulated genes using the Metascape software [94]
(accessed May 2022).

### 499 WES, variation calling and filtering

Genomic DNA from peripheral blood was extracted using the 500 standard phenol-chloroform method. The DNA of all 159 CPT 501 patients was fragmented and the exome was captured using the 502 Agilent SureSelect Human All Exon V6 kit. The captured DNA 503 was sequenced with 100 bp pair-end reads using the 504 BGISEQ2000 platform, following the manufacturer's 505 instructions. Each sample yielded an average of 13.3 Gb of raw 506 data with an average depth of 132 and a coverage ratio of 507 99.84% of the captured target region of 60.46 M. Over 98% 508 (average  $\sim$ 92.9%) of the bases had a phred quality score > 30. 509 For the variation calling, the raw reads were filtered by 510 SOAPnuke [95] and then mapped to the human genome 511 reference (UCSC/GRCh37/hg19) using the Burrows-Wheeler 512 Aligner (BWA-MEM, version 0.7.10) [96]. Variants were called 513

514	using the Genome Analysis Tool Kit (GATK, version 4.1) [97]. To
515	validate the accuracy of the variation calling, 208 Chinese Han
516	individuals from the 1000 Genomes Project were selected as a
517	control to perform principal component analysis (PCA). This
518	allowed us to remove the false positive WES variations by setting
519	genotype quality > 30, the minimum read depth of 20 for each
520	genotype, and an additional setting of the allele balance of 0.3 for
521	each heterozygous genotype. Furthermore, all indels with allele
522	lengths greater than 10 bp were removed. The Variant Effect
523	Predictor (VEP) [98] was used to annotate and classify all the
524	variants. Subsequently, the variants were filtered based on their
525	frequency in public database gnomAD
526	(https://gnomad.broadinstitute.org/) and the bi-allelic LoF
527	variants (frameshift_variant, splice_acceptor_variant,
528	splice_donor_variant, start_lost, stop_gained and stop_lost) with
529	MAF < 0.001 were retained.
530	LoF excess test for pathway gene sets

After obtaining the VCF file of LoF variations, the software rvtest[99] was used to test the LoF excess for each gene set from the biological processes or KEGG pathways. The burden test was performed using the CMC model, with a control population

- consisting of 208 Chinese Han individuals selected from the
- <sup>536</sup> 1000 Genomes Project as the control population against the 159
- 537 patients with CPT. The VCF files containing the variations
- information of both the 159 patients and the 208 control
- individuals were at the service for request. The genes
- corresponding to the biological processes were obtained from
- <sup>541</sup> http://amigo.geneontology.org/amigo/term/GO:0008150, with
- the organism selected as Homo sapiens. The genes of KEGG
- 543 pathways were downloaded from
- 544 https://www.genome.jp/kegg/.

545

#### 546 **Tables**

#### Table 1. LoF excess in 21 biological processes enriched in the GO

548 database

Co Torm	Num.L	Num.C	Num.C	0	P.fish	P.rvte
Go Term	oF	ase	trl	R	er	st
regulation of MARK cascade CO:0043408	34	35	1	35	4.13E-	2.81E-
regulation_or_mAr K_caseaue_00.0043408	54	55	1	55	13	12
monostomia ion homosotoria CO.0050801	34 33	22	0	33	2.74E-	5.69E-
monoatomic_ion_nomeostasis_GO:0050801		33			12	12
	27 29	20	0	29	1.13E-	1.38E-
regulation_ol_normone_levels_GO:0010817		29			10	10
	22	20	0	20	2.81E-	1.38E-
inflammatory_response_GO:0006954	33	28	0	28	10	10
positive_regulation_of_cytokine_production_GO:00	27	24	0	24	1.03E-	3.14E-
01819	27 24	24	0	24	08	09
······································	10			22	2.50E-	1.46E-
ossification_GO:0001503	18	23	0	23	08	08

regulation_of_monoatomic_ion_transport_GO:0043	42	25	2	17.	4.86E-	3.20E-
269	42	33	2	5	12	11
	12	17	0	17	4.45E-	1.37E-
myeloid_leukocyte_differentiation_GO:0002573	13	17	0	17	06	06
	11	16	0	16	1.03E-	2.89E-
regulation_of_bone_resorption_GO:0045124	11	16	0	16	05	06
	16	16	0	16	1.03E-	2.89E-
regulation_of_cell_growth_GO:0001558	16	16	0	16	05	06
contraction of the second state of the second	15	16	1	16	1.03E-	1.51E-
response_to_lipopolysaccharide_GO:0032496	15	16	1	16	05	05
	15	14	1	1.4	5.41E-	6.58E-
ameboldal-type_cell_migration_GO:0001667	15	14	1	14	05	05
regulation of his line CO.0051009	14	14	0	14	5.41E-	1.28E-
regulation_of_binding_GO:0031098	14	14	0	14	05	05
negative regulation of locamation CO10040012	27	27	2	13.	6.33E-	1.73E-
negative_regulation_of_locomotion_60.0040015	27	27	2	5	09	08
negative regulation of transport CO:0051051	26	26	2	12	1.59E-	2.94E-
negative_regulation_or_transport_60:0051051	50	50	5	12	11	11
call membrachasis CO:0000002	22	22	2	11.	1.94E-	3.62E-
cen_morphogenesis_GO:0000902	25	25	2	5	07	07
skalatal system davalarmant CO:0001501	26	22	2	11.	1.94E-	3.62E-
skeletar_system_development_GO:0001501	20	25	2	5	07	07
regulation of T call preliferation CO(0042120	10	11	1	11	0.0006	0.0005
regulation_or_r_cen_promeration_00.0042129	10	11	1	11	12	9
response to nutrient CO-0007584	0	11	0	11	0.0006	0.0001
response_to_nument_00.0007384	)	11	0	11	12	17
$negative\_regulation\_of\_response\_to\_external\_stimu$	24	21	2	10.	1.03E-	7.66E-
lus_GO:0032102	24	21	2	5	06	07
B cell mediated immunity GO:0019724	10	10	0	10	0.0013	0.0001
b_cen_mediated_mmunity_00.0017724	10	10	0	10	48	17
extracellular matrix organization GO:0030198	36	36	4	9	1.24E-	2.77E-
extracential_matrix_organization_00.0050170	50	50	-	,	10	10
multicellular_organismal_homeostasis_GO:004887	32	35	4	8.7	2.85E-	6.09E-
1	52	55	-	5	10	10
autophagy GO:0006914	16	17	2	85	4.03E-	3.06E-
	10	17	2	0.5	05	05
positive_regulation_of_cold-	6	8	0	8	0.0119	0.0010
induced_thermogenesis_GO:0120162	0	0	0	0	04	72
positive_regulation_of_hydrolase_activity_GO:005	38	40	5	8	1.75E-	4.54E-
1345	50	40	5	0	11	11
positive_regulation_of_cell_development_GO:0010	22	19	4	4.7	0.0001	8.60E-
720		.,	•	5	1	05
cell junction organization GO:0034330	18	18	4	4.5	0.0002	0.0001
					17	71

hatarotypic call call adhasion GO:0034113	5	4	1	4	0.1707	0.0956
helefotypic_cen-cen_adhesion_00.0034115	5	4	1	4	59	34
andedam dauslammant CO:0007402	2	2	0	2	0.3202	0.0466
endoderm_development_60.0007492	3	3	0	3	44	8
tissue remodeling GO:0048771	2	2	1	2	0.3202	0.1986
lissue_remodening_00.0048771	3 3	3	1	5	44	17
regulation_of_homotypic_cell-	2	2	0	2	0.5810	0.1048
cell_adhesion_GO:0034110	2	2	0	2	98	16
regulation of p38MAPK cascade GO:1000744	2	2	0	2	0.5810	0.1048
regulation_or_p36MArK_cascade_00.1900/44	2	2	0	2	98	16
regulation_of_SMAD_protein_signal_transduction_	1	2	0	2	0.5810	0.1048
GO:0060390	1	2	0	Ζ	98	16
developmental sigmentation CO:00/2066	2	2	2	15	0.6560	0.4486
developmental_pigmentation_60:0048000	3	5	2	1.5	41	44
innormation CO.0060284	1	1	0	1		0.2520
IIIIei vauoii_00:0000384	1	1	U	1	1	78

549

## 550 Table 2. KEGG pathway enrichment of THE suffering from LoF

#### 551 variations

Category	Term	Description	LogP	Log(q-value)	InTerm_
KEGG Pathway	hsa04380	Osteoclast differentiation	-4.83279	-2.616	8/128
KEGG Pathway	hsa05152	Tuberculosis	-4.58891	-2.616	9/180
KEGG Pathway	hsa05418	Fluid shear stress and atherosclerosis	-4.5734	-2.616	8/139
KEGG Pathway	hsa05204	Chemical carcinogenesis - DNA adducts	-4.56047	-2.616	6/69
KEGG Pathway	hsa04010	MAPK signaling pathway	-2.99947	-1.453	9/294
KEGG Pathway	hsa04020	Calcium signaling pathway	-2.95648	-1.451	8/240
KEGG Pathway	hsa04151	PI3K-Akt signaling pathway	-2.45406	-1.112	9/354
KEGG Pathway	hsa00280	Valine, leucine and isoleucine degradation	-2.09919	-0.836	3/48
KEGG Pathway	hsa04750	Inflammatory mediator regulation of TRP channels	-2.00287	-0.799	4/98

552

## 553 Table 3. The list of CPT-causing LoF variations

C H R	PO S	R EF	A L T	Consequence	Sy mb ol	Biotype	gnom AD_E AS_A F	HGVSc	HGVSp
1	268 572 34	A	G	splice_acceptor_va riant&NMD_transc ript_variant	RP S6 KA 1	nonsense _mediate d_decay	0	ENST00000525 525.1:c.64- 2A>G	

1	110 201 481	C	Т	stop_gained	GS TM	protein_c oding	0	ENST00000326 729.5:c.406C>	ENSP00000316 471.5:p.Gln136
	110		А		4 GS			I ENST0000326	ENSP00000316
1	201	А	А	frameshift variant	TM	protein_c	5.44E-	729.5:c.419 42	471.5:p.Phe141
	494		G	_	4	oding	05	– 0insAG	GlyfsTer17
					AR				-
	155	~			HG	protein_c	0.0002	ENST00000368	ENSP00000357
1	942	G	А	stop_gained	EF	oding	787	315.4:c.58C>T	298.3:p.Arg20T
	054				2				er
	161				FC	protein c	0.0002	ENST0000367	ENSP00000356
1	514	CT	С	frameshift_variant	GR	oding	175	967 3·c 517del	944.3:p.Arg173
	550				3A July 175		707.5.e.517dei	GlyfsTer14	
	169			splice donor varia	SE	protein c	0.0003	ENST00000333	
1	699	С	Т	nt	LE	oding	343	360.7:c.715+1	
	572					8		G>A	
	175				TN	protein_c	5.44E-	ENST00000239	ENSP00000239
1	096	С	G	stop_gained	N	oding	05	462.4:c.3021C>	462.4:p.Tyr100
	197							G	7Ter
•	707	G	-	splice_donor_varia	TG	protein_c	0.0001	ENST00000444	
2	803	С	Т	nt	FA	oding	906	975.1:c.58+1G	
	15							>A	
					SI				
	486				SL	protein c	5 57F-	ENST00000358	ENSP00000351
3	486 693	G	A	stop_gained	SL C2 6A	protein_c	5.57E- 05	ENST00000358 747.6:c.625C>	ENSP00000351 597.6:p.Gln209
3	486 693 75	G	A	stop_gained	SL C2 6A 6	protein_c oding	5.57E- 05	ENST00000358 747.6:c.625C> T	ENSP00000351 597.6:p.Gln209 Ter
3	486 693 75 499	G	A	stop_gained	SL C2 6A 6 MS	protein_c oding	5.57E- 05	ENST00000358 747.6:c.625C> T ENST00000296	ENSP00000351 597.6:p.Gln209 Ter ENSP00000296
3	486 693 75 499 398	G G	A	stop_gained	SL C2 6A 6 MS T1	protein_c oding protein_c	5.57E- 05 0.0001	ENST00000358 747.6:c.625C> T ENST00000296 474.3:c.1186C>	ENSP00000351 597.6:p.Gln209 Ter ENSP00000296 474.3:p.Arg396
3	486 693 75 499 398 57	G G	A A	stop_gained	SL C2 6A 6 MS T1 R	protein_c oding protein_c oding	5.57E- 05 0.0001 631	ENST00000358 747.6:c.625C> T ENST00000296 474.3:c.1186C> T	ENSP00000351 597.6:p.Gln209 Ter ENSP00000296 474.3:p.Arg396 Ter
3	486 693 75 499 398 57 130	G G	A A	stop_gained	SL C2 6A 6 MS T1 R CO	protein_c oding protein_c oding	5.57E- 05 0.0001 631	ENST00000358 747.6:c.625C> T ENST00000296 474.3:c.1186C> T ENST00000265	ENSP00000351 597.6:p.Gln209 Ter ENSP00000296 474.3:p.Arg396 Ter
3 3 3	486 693 75 499 398 57 130 120	G G	A A T	stop_gained stop_gained splice_donor_varia	SL C2 6A 6 MS T1 R CO L6	protein_c oding protein_c oding protein_c	5.57E- 05 0.0001 631 0.0002	ENST00000358 747.6:c.625C> T ENST00000296 474.3:c.1186C> T ENST00000265 379.6:c.4227+1	ENSP00000351 597.6:p.Gln209 Ter ENSP00000296 474.3:p.Arg396 Ter
3 3 3	486 693 75 499 398 57 130 120 699	G G	A A T	stop_gained stop_gained splice_donor_varia nt	SL C2 6A MS T1 R CO L6 A5	protein_c oding protein_c oding protein_c oding	5.57E- 05 0.0001 631 0.0002 753	ENST0000358 747.6:c.625C> T ENST00000296 474.3:c.1186C> T ENST00000265 379.6:c.4227+1 G>T	ENSP00000351 597.6:p.Gln209 Ter ENSP00000296 474.3:p.Arg396 Ter
3 3 3	486 693 75 499 398 57 130 120 699 130	G G G	A A T	stop_gained stop_gained splice_donor_varia nt	SL C2 6A MS T1 R CO L6 A5 CO	protein_c oding protein_c oding protein_c oding	5.57E- 05 0.0001 631 0.0002 753	ENST0000358 747.6:c.625C> T ENST0000296 474.3:c.1186C> T ENST0000265 379.6:c.4227+1 G>T ENST0000265	ENSP00000351 597.6:p.Gln209 Ter ENSP00000296 474.3:p.Arg396 Ter
3 3 3 3	486 693 75 499 398 57 130 120 699 130 189	G G T	A A T	stop_gained stop_gained splice_donor_varia nt splice_donor_varia	SL C2 6A MS T1 R CO L6 A5 CO L6	protein_c oding protein_c oding protein_c oding protein_c oding	5.57E- 05 0.0001 631 0.0002 753 0.0001	ENST00000358 747.6:c.625C> T ENST00000296 474.3:c.1186C> T ENST00000265 379.6:c.4227+1 G>T ENST00000265 379.6:c.7574+2	ENSP00000351 597.6:p.Gln209 Ter ENSP00000296 474.3:p.Arg396 Ter
3 3 3	486 693 75 499 398 57 130 120 699 130 189 813	G G T	A A T C	stop_gained stop_gained splice_donor_varia nt splice_donor_varia nt	SL C2 6A MS T1 R CO L6 A5 CO L6 A5	protein_c oding protein_c oding protein_c oding protein_c oding	5.57E- 05 0.0001 631 0.0002 753 0.0001 126	ENST00000358 747.6:c.625C> T ENST00000296 474.3:c.1186C> T ENST00000265 379.6:c.4227+1 G>T ENST00000265 379.6:c.7574+2 T>C	ENSP00000351 597.6:p.Gln209 Ter ENSP00000296 474.3:p.Arg396 Ter
3 3 3	486 693 75 499 398 57 130 120 699 130 189 813 190	G G T	A A T C	stop_gained stop_gained splice_donor_varia nt splice_donor_varia nt	SL C2 6A 6 MS T1 R CO L6 A5 CO L6 A5 IL1	protein_c oding protein_c oding protein_c oding protein_c oding	5.57E- 05 0.0001 631 0.0002 753 0.0001 126	ENST00000358 747.6:c.625C> T ENST00000296 474.3:c.1186C> T ENST00000265 379.6:c.4227+1 G>T ENST00000265 379.6:c.7574+2 T>C ENST00000412	ENSP00000351 597.6:p.Gln209 Ter ENSP00000296 474.3:p.Arg396 Ter
3 3 3 3	486 693 75 499 398 57 130 120 699 130 189 813 190 333	G G T T	A A T C	stop_gained stop_gained splice_donor_varia nt splice_donor_varia nt	SL C2 6A MS T1 R CO L6 A5 CO L6 A5 IL1 RA	protein_c oding protein_c oding protein_c oding protein_c oding protein_c oding	5.57E- 05 0.0001 631 0.0002 753 0.0001 126 0.0005 515	ENST00000358 747.6:c.625C> T ENST00000296 474.3:c.1186C> T ENST00000265 379.6:c.4227+1 G>T ENST00000265 379.6:c.7574+2 T>C ENST00000412 080.1:c.47+2T>	ENSP00000351 597.6:p.Gln209 Ter ENSP00000296 474.3:p.Arg396 Ter
3 3 3 3	486 693 75 499 398 57 130 120 699 130 189 813 190 333 145	G G T T	A A T C	stop_gained stop_gained splice_donor_varia nt splice_donor_varia nt splice_donor_varia nt	SL C2 6A 6 MS T1 R CO L6 A5 CO L6 A5 IL1 RA P	protein_c oding protein_c oding protein_c oding protein_c oding protein_c oding	5.57E- 05 0.0001 631 0.0002 753 0.0001 126 0.0005 515	ENST00000358 747.6:c.625C> T ENST00000296 474.3:c.1186C> T ENST00000265 379.6:c.4227+1 G>T ENST00000265 379.6:c.7574+2 T>C ENST00000412 080.1:c.47+2T> C	ENSP00000351 597.6:p.Gln209 Ter ENSP00000296 474.3:p.Arg396 Ter
3 3 3 3	486 693 75 499 398 57 130 120 699 130 189 813 190 333 145 154	G G T T	A A T C	stop_gained stop_gained splice_donor_varia nt splice_donor_varia nt splice_donor_varia nt	SL C2 6A MS T1 R CO L6 A5 CO L6 A5 IL1 RA P TL	protein_c oding protein_c oding protein_c oding protein_c oding protein_c oding	5.57E- 05 0.0001 631 0.0002 753 0.0001 126 0.0005 515 0.0004	ENST00000358 747.6:c.625C> T ENST00000296 474.3:c.1186C> T ENST00000265 379.6:c.4227+1 G>T ENST00000265 379.6:c.7574+2 T>C ENST00000412 080.1:c.47+2T> C	ENSP00000351 597.6:p.Gln209 Ter ENSP00000296 474.3:p.Arg396 Ter
3 3 3 3 3	486 693 75 499 398 57 130 120 699 130 189 813 190 333 145 154 625	G G T T	A A T C C T	stop_gained stop_gained splice_donor_varia nt splice_donor_varia nt splice_donor_varia nt	SL C2 6A MS T1 R CO L6 A5 CO L6 A5 IL1 RA P TL R2	protein_c oding protein_c oding protein_c oding protein_c oding protein_c oding	5.57E- 05 0.0001 631 0.0002 753 0.0001 126 0.0005 515 0.0004 349	ENST00000358 747.6:c.625C> T ENST00000296 474.3:c.1186C> T ENST00000265 379.6:c.4227+1 G>T ENST00000265 379.6:c.7574+2 T>C ENST00000412 080.1:c.47+2T> C ENST00000260 010.6:c.1339C>	ENSP00000351 597.6:p.Gln209 Ter ENSP00000296 474.3:p.Arg396 Ter 
3 3 3 3 4	486 693 75 499 398 57 130 120 699 130 189 813 190 333 145 154 625 398	G G T T C	A A T C C T	stop_gained stop_gained splice_donor_varia nt splice_donor_varia nt splice_donor_varia nt splice_donor_varia	SL C2 6A 6 MS T1 R CO L6 A5 CO L6 A5 IL1 RA P TL R2	protein_c oding protein_c oding protein_c oding protein_c oding protein_c oding protein_c oding	5.57E- 05 0.0001 631 0.0002 753 0.0001 126 0.0005 515 0.0004 349	ENST00000358 747.6:c.625C> T ENST00000296 474.3:c.1186C> T ENST00000265 379.6:c.4227+1 G>T ENST00000265 379.6:c.7574+2 T>C ENST00000412 080.1:c.47+2T> C ENST00000260 010.6:c.1339C> T	ENSP00000351 597.6:p.Gln209 Ter ENSP00000296 474.3:p.Arg396 Ter 
3 3 3 3 4	486 693 75 499 398 57 130 120 699 130 189 813 190 333 145 154 625 398 140 012	G G T T C	A A T C C T	stop_gained stop_gained splice_donor_varia nt splice_donor_varia nt splice_donor_varia nt splice_donor_varia nt	SL C2 6A MS T1 R CO L6 A5 CO L6 A5 IL1 RA P TL R2 CD	protein_c oding protein_c oding protein_c oding protein_c oding protein_c oding protein_c	5.57E- 05 0.0001 631 0.0002 753 0.0001 126 0.0005 515 0.0004 349	ENST0000358 747.6:c.625C> T ENST0000296 474.3:c.1186C> T ENST0000265 379.6:c.4227+1 G>T ENST0000265 379.6:c.7574+2 T>C ENST00000412 080.1:c.47+2T> C ENST00000260 010.6:c.1339C> T	ENSP00000351 597.6:p.Gln209 Ter ENSP00000296 474.3:p.Arg396 Ter 
3 3 3 3 4 5	486 693 75 499 398 57 130 120 699 130 189 813 190 333 145 154 625 398 140 012 655	G G T T C	A T C T G	stop_gained stop_gained splice_donor_varia nt splice_donor_varia nt splice_donor_varia nt splice_donor_varia splice_donor_varia splice_donor_varia splice_donor_varia	SL C2 6A 6 MS T1 R CO L6 A5 CO L6 A5 IL1 RA P TL R2 CD 14	protein_c oding protein_c oding protein_c oding protein_c oding protein_c oding protein_c oding	5.57E- 05 0.0001 631 0.0002 753 0.0001 126 0.0005 515 0.0004 349 0	ENST0000358 747.6:c.625C> T ENST00000296 474.3:c.1186C> T ENST00000265 379.6:c.4227+1 G>T ENST00000265 379.6:c.7574+2 ENST00000412 080.1:c.47+2T> C ENST00000412 O10.6:c.1339C> T ENST00000302	ENSP00000351 597.6:p.Gln209 Ter ENSP00000296 474.3:p.Arg396 Ter 

6	123 702 514	СТ	C	frameshift_variant &splice_region_var iant	TR DN	protein_c oding	0.0002 441	ENST00000334 268.4:c.1186del	ENSP00000333 984.4:p.Lys396 AsnfsTer27
6	154 567 863	С	Т	stop_gained	OP RM 1	protein_c oding	0.0002 719	ENST00000337 049.4:c.1201C> T	ENSP00000338 381.4:p.Arg401 Ter
6	161 507 701	Т	C	splice_donor_varia nt	MA P3 K4	protein_c oding	0.0001 679	ENST00000348 824.7:c.2556+2 T>C	
7	931 252 41	C	Т	start_lost	CA LC R	protein_c oding	0.0007 849	ENST00000359 558.2:c.3G>A	ENSP00000352 561.2:p.Met1?
7	150 708 074	G G T A A	G	splice_donor_varia nt&intron_variant	NO S3	protein_c oding	0	ENST00000297 494.3:c.2984+3 _2984+6del	
8	420 378 06	G	Т	stop_gained	PL AT	protein_c oding	5.44E- 05	ENST00000220 809.4:c.1176C> A	ENSP00000220 809.4:p.Tyr392 Ter
9	131 467 786	C	Т	stop_gained	PK N3	protein_c oding	0	ENST00000291 906.4:c.229C> T	ENSP00000291 906.4:p.Arg77T er
1 0	514 474 4	С	Т	stop_gained	AK R1 C3	protein_c oding	0	ENST00000380 554.3:c.748C> T	ENSP00000369 927.3:p.Arg250 Ter
1 0	525 501 3	A G	A	frameshift_variant	AK R1 C4	protein_c oding	5.44E- 05	ENST00000263 126.1:c.738del	ENSP00000263 126.1:p.Lys247 AsnfsTer8
1 0	711 758 65	A T	A	frameshift_variant	TA CR 2	protein_c oding	0.0003 262	ENST00000373 306.4:c.214del	ENSP00000362 403.4:p.Ile72Se rfsTer53
1 0	811 112 41	Α	Т	splice_acceptor_va riant	PPI F	protein_c oding	0.0003 81	ENST00000225 174.3:c.316- 2A>T	
1 0	106 025 900	A C	A	frameshift_variant	GS TO 1	protein_c oding	5.44E- 05	ENST00000369 710.4:c.427del	ENSP00000358 724.4:p.Leu143 SerfsTer12
1 1	645 079 23	Т	C	splice_acceptor_va riant&NMD_transc ript_variant	RA SG RP 2	nonsense _mediate d_decay	0.0001 852	ENST00000445 445.1:c.372- 2A>G	

1 1	653 747 90	G	A	stop_gained&NMD _transcript_variant	MA P3 K1 1	nonsense _mediate d_decay	0.0002 229	ENST00000524 848.1:c.556C> T	ENSP00000431 506.1:p.Gln186 Ter
1 2	188 546 25	С	Т	splice_donor_varia nt	PL CZ 1	protein_c oding	0.0002 179	ENST00000266 505.7:c.949+1 G>A	
1 2	188 903 16	C	G	splice_donor_varia nt&non_coding_tra nscript_variant	PL CZ 1	processed _transcri pt	0.0002 721	ENST00000541 109.1:n.235+1 G>C	
1 2	685 491 50	G	A	stop_gained	IFN G	protein_c oding	0	ENST00000229 135.3:c.484C> T	ENSP00000229 135.3:p.Arg162 Ter
1 7	380 691 2	G	A	stop_gained	P2 RX 1	protein_c oding	0	ENST00000225 538.3:c.538C> T	ENSP00000225 538.3:p.Arg180 Ter
1 7	294 969 23	CT G TT	C	frameshift_variant	NF 1	protein_c oding	0	ENST00000356 175.3:c.499_50 2del	ENSP00000348 498.3:p.Cys167 GlnfsTer10
1 7	294 970 03	С	Т	stop_gained	NF 1	protein_c oding	0	ENST00000356 175.3:c.574C> T	ENSP00000348 498.3:p.Arg192 Ter
1 7	295 333 15	C	Т	stop_gained	NF 1	protein_c oding	5.44E- 05	ENST00000356 175.3:c.1318C> T	ENSP00000348 498.3:p.Arg440 Ter
1 7	295 534 92	С	Т	stop_gained	NF 1	protein_c oding	0	ENST00000356 175.3:c.2041C> T	ENSP00000348 498.3:p.Arg681 Ter
1 7	295 574 01	G	A	splice_donor_varia nt	NF 1	protein_c oding	0	ENST00000356 175.3:c.3113+1 G>A	
1 7	295 629 81	C	Т	stop_gained	NF 1	protein_c oding	0	ENST00000356 175.3:c.3916C> T	ENSP00000348 498.3:p.Arg130 6Ter
1 7	295 761 11	С	Т	stop_gained	NF 1	protein_c oding	0	ENST00000356 175.3:c.4084C> T	ENSP00000348 498.3:p.Arg136 2Ter
1 7	296 793 66	C	Т	stop_gained	NF 1	protein_c oding	0	ENST00000356 175.3:c.7486C> T	ENSP00000348 498.3:p.Arg249 6Ter
1 7	296 843 26	С	Т	stop_gained	NF 1	protein_c oding	0	ENST00000356 175.3:c.7846C> T	ENSP00000348 498.3:p.Arg261 6Ter

1	397	Δ			KB	protein c		ENST00000301	ENSP00000301
1	684	СТ	А	frameshift_variant	Т16	oding	0	653.4:c.475_47	653.3:p.Ser159
/	64	CI			110	ounig		6del	Ter
1	397		G		VD			ENST00000301	ENSP00000301
1	684	G	С	frameshift_variant	KK	protein_c	0	653.4:c.473_47	653.3:p.Ser159
/	67		А		116	oding		4insTG	AlafsTer17
	179							ENST00000458	
1	552	С	Т	splice_acceptor_va	JA	protein_c	0	235.1:c13-	
9	40			riant	K3	oding		1G>A	
	407							ENST00000579	ENSP00000471
1	408	G	А	stop_gained	AK	protein_c	0	047.1:c.1270C>	369.1:p.Arg424
9	62				T2	oding		Т	Ter
	496							ENST00000252	ENSP00000252
1	578	G	А	stop_gained	HR	protein_c	0	825.4:c.649C>	825.3:p.Arg217
9	46			1-0	С	oding		Т	Ter
	547				LIL			ENST00000314	ENSP00000319
1	785	G	G	frameshift variant	RB	protein_c	0	446.5:c.1748 1	960.5:p.Glu583
9	81	TT		—	2	oding		749del	AlafsTer4
	547				LIL				ENSP00000319
1	785	СТ	С	frameshift variant	RB	protein_c	0	ENST00000314	960.5:p.Arg582
9	86				2	oding		446.5:c.1744del	GlyfsTer68
	550		С		LIL			ENST00000251	ENSP00000251
1	863	С	G	frameshift variant	RA	protein_c	0	376.3:c.511 51	376.3:p.His171
9	56		Т		2	oding		2insGT	ArgfsTer16
	550	т			LIL			ENST0000251	ENSP00000251
1	863	G	т	frameshift variant	RA	protein_c	0	376.3:c.514_51	376.3:p.Ala172
9	58	C			2	oding		5del	ProfsTer27
	551	C			- LIL			ENST00000324	ENSP00000315
1	436	G	А	ston gained	RB	protein_c	0.0007	602.7:c.582G>	997.7:p.Trp194
9	09	-		F=0	1	oding	068	A	Ter
	551				LIL			ENST00000324	ENSP00000315
1	466	G	А	stop gained	RB	protein_c	0.0001	602.7:c.1559G	997.7:p.Trp520
9	27	U		stop_suited	1	oding	643	>A	Ter
	551			frameshift variant	LIL.			FNST00000270	101
1	792	А	Δ	& splice region var	RB	protein_c	0.0004	452 2·c 1200+1	
9	43	G	11	iant	4	oding	92	del	
	551			iuiit	тп			ENST00000270	
1	792	т	Δ	splice_donor_varia	RB	protein_c	0.0005	452 2·c 1200+2	
9	152	1	Л	nt	КD 4	oding	468	432.2.0.1200+2 Τ\Δ	
	421	Δ			7			FNST0000241	ENSP0000340
2	950	л С	Δ	frameshift variant	SG	protein_c	5.44E-	458 4·c 115 11	608 4·n Pro30 A
0	550 65	C	А	mannesinn_värfählt	K2	oding	05		ouo.4.p.11039A
	03	U						odei	sinster1/

#### 555 Figure Legends

Fig1. Identification of differentially expressed genes associated 556 with CPT in the transcriptome sequencing (a) Volcano plot for the 557 comparison between the 3 CPT (JG159\_nonNF1, JG250\_NF1 and 558 [G252 NF1] and 2 healthy individuals (GDZ001 Control and 559 GDZ002\_Control). The cutoff values fold change >2 and FDR < 0.01 560 were utilized to identify differentially expressed genes. Non-561 changed genes were shown in black color. Red color is indicative 562 of the up-regulated genes and the down-regulated genes. (b) 563 Heatmap plot of differentially expressed genes. The Pearson 564 correlation distance metric and the average linkage clustering 565 algorithm were used. (c) the GO enrichment of the 179 up-566 regulated genes in the transcriptome. X-axis indicates the -log(P) 567 in which P is the probability that the genes are enriched in the 568 biological process in GO database. Here the threshold of -log(P) is 569 set as 2, indicating the P value 0.01. 570

Fig2. The 179 up-regulated genes in patients with CPT significantly enriched in 40 biological processes in the GO biological processes (the Bonferroni corrected P= 0.05/100=5e-4) among which 21 revealed the LoF excesses (under the criteria OR >10 and P > 0.01). X-axis indicates the biological processes from GO database and Y-axis indicates the odd ratio (OR) that the

LoF mutations enrich in the biological process between 159 CPT
cases and 208 controls. The number above the bar in each process
is the P values indicating the enrichment of LoF mutations in this
process.

Fig3. The KEGG pathway enrichment analysis and the LoF 581 excesses of the transcriptome high expression (THE) gene set 582 suffering from rare genomic LoF variations. (a) The KEGG 583 enrichment of THE carrying the LoF mutations. X-axis indicates 584 the -log(P) in which P is the probability that the genes are 585 enriched in the pathway. Here the threshold of -log(P) is set as 2, 586 indicating the P value 0.01. (b) the LoF excesses of the significant 587 KEGG pathways enriched by THE. X-axis indicates the pathways 588 from KEGG database and Y-axis indicates the odd ratio(OR) that 589 the LoF mutations enrich in the pathway between 159 CPT cases 590 and 208 controls. The numbers above the bars are the -log(P) in 591 which P indicate the enrichment of LoF mutations in the pathway. 592 Here the threshold of  $-\log(P)$  is 2, indicating the threshold P 0.01. 593 594

595 **Data availability** 

<sup>596</sup> Both RNA-seq and WES data are at the service for request.

### 597 Authors information

598	Hui Huang, Huanhuan Peng and Haibo Mei conceived and
599	designed the study. Guanghui Zhu and Yu Zheng collected the
600	samples and performed the experimental analysis. Nan Li
601	performed the data analysis and wrote the manuscript. All the
602	authors read and approved the final manuscript.

#### **Declaration of conflicting interests**

The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

#### 607 Ethics declarations

The experimental protocol was approved by the Research
Ethics Committee of Hunan Children's Hospital. Informed
consent was obtained from every patient.

### 611 Fundings

Opening fundings of Hunan Provincial Key Laboratory of

613 Pediatric Orthopedics

## 614 **References**

- 615 [1]. Hefti, F., et al., Congenital pseudarthrosis of the tibia: history, etiology, classification, and
- epidemiologic data. J Pediatr Orthop B, 2000. 9(1): p. 11-5.
- 617 [2]. Shannon, C.E., A.J. Huser and D. Paley, Cross-Union Surgery for Congenital Pseudarthrosis of the
- 618 Tibia. Children (Basel), 2021. 8(7).
- [3]. Han, J., et al., A benign form of congenital anterolateral bowing of the tibia associated with
- 620 ipsilateral polydactyly of the hallux: case report and literature review. Am J Med Genet A, 2012. 158A(7):621 p. 1742-9.
- [4]. Zheng, Y., et al., Case series of congenital pseudarthrosis of the tibia unfulfilling
  neurofibromatosis type 1 diagnosis: 21% with somatic NF1 haploinsufficiency in the periosteum. Hum
  Genet, 2022. 141(8): p. 1371-1383.
- 625 [5]. Xu, J., et al., Clinical characteristics and in silico analysis of congenital pseudarthrosis of the tibia
- 626 combined with neurofibromatosis type 1 caused by a novel NF1 mutation. Front Genet, 2022. 13: p.627 991314.
- 628 [6]. Brekelmans, C., et al., Neurofibromatosis type 1-related pseudarthrosis: Beyond the pseudarthrosis
  629 site. Hum Mutat, 2019. 40(10): p. 1760-1767.
- 630 [7]. Zhu, G., et al., Identification and characterization of NF1 and non-NF1 congenital pseudarthrosis
- of the tibia based on germline NF1 variants: genetic and clinical analysis of 75 patients. Orphanet J
  Rare Dis, 2019. 14(1): p. 221.
- [8]. Lee, S.M., et al., Is double inactivation of the Nf1 gene responsible for the development ofcongenital pseudarthrosis of the tibia associated with NF1? J Orthop Res, 2012. 30(10): p. 1535-40.
- [9]. El-Hoss, J., et al., A murine model of neurofibromatosis type 1 tibial pseudarthrosis featuring
  proliferative fibrous tissue and osteoclast-like cells. J Bone Miner Res, 2012. 27(1): p. 68-78.
- [10]. Sant, D.W., et al., Evaluation of somatic mutations in tibial pseudarthrosis samples in
  neurofibromatosis type 1. J Med Genet, 2015. 52(4): p. 256-61.
- [11]. Stevenson, D.A., et al., Double inactivation of NF1 in tibial pseudarthrosis. Am J Hum Genet, 2006.
  79(1): p. 143-8.
- 641 [12]. Leskelä, H.V., et al., Congenital pseudarthrosis of neurofibromatosis type 1: impaired osteoblast
  642 differentiation and function and altered NF1 gene expression. Bone, 2009. 44(2): p. 243-50.
- 643 [13]. Sakamoto, A., et al., Congenital pseudarthrosis of the tibia: analysis of the histology and the NF1
  644 gene. J Orthop Sci, 2007. 12(4): p. 361-5.
- [14]. Kamiya, N., et al., Targeted Disruption of NF1 in Osteocytes Increases FGF23 and Osteoid With
  Osteomalacia-like Bone Phenotype. J Bone Miner Res, 2017. 32(8): p. 1716-1726.
- 647 [15]. Yang, G., et al., Serum-derived exosomes from neurofibromatosis type 1 congenital tibial
- pseudarthrosis impaired bone by promoting osteoclastogenesis and inhibiting osteogenesis. Exp Biol
  Med (Maywood), 2021. 246(2): p. 130-141.
- [16]. Julien, A., et al., FGFR3 in Periosteal Cells Drives Cartilage-to-Bone Transformation in Bone
  Repair. Stem Cell Reports, 2020. 15(4): p. 955-967.
- [17]. Qu, H., et al., The effects of vasoactive intestinal peptide on RANKL-induced osteoclast
  formation. Ann Transl Med, 2021. 9(2): p. 127.
- [18]. Yang, G., et al., Serum-derived exosomes from neurofibromatosis type 1 congenital tibial
- 655 pseudarthrosis impaired bone by promoting osteoclastogenesis and inhibiting osteogenesis.
- Experimental Biology and Medicine, 2021. 246(2): p. 130-141.

- 657 [19]. Liu, Y., et al., New insights into pathogenesis of congenital pseudarthrosis of tibia in children
- using periosteum proteomics analysis. Rapid Commun Mass Spectrom, 2022. 36(21): p. e9374.
- [20]. Kenkre, J.S. and J. Bassett, The bone remodelling cycle. Ann Clin Biochem, 2018. 55(3): p. 308-327.
- [21]. Salhotra, A., et al., Mechanisms of bone development and repair. Nature Reviews Molecular Cell
  Biology, 2020. 21(11): p. 696-711.
- 663 [22]. Chan, W., et al., Regulation and Role of Transcription Factors in Osteogenesis. Int J Mol Sci, 2021.
- 664 22(11).
- [23]. Yahara, Y., et al., The origins and roles of osteoclasts in bone development, homeostasis and repair.
  Development, 2022. 149(8).
- [24]. Cushion, T.D., et al., De novo mutations in the beta-tubulin gene TUBB2A cause simplified gyral
  patterning and infantile-onset epilepsy. Am J Hum Genet, 2014. 94(4): p. 634-41.
- 669 [25]. Guella, I., et al., De Novo Mutations in YWHAG Cause Early-Onset Epilepsy. Am J Hum Genet,
  670 2017. 101(2): p. 300-310.
- 671 [26]. Kanca, O., et al., De Novo Variants in WDR37 Are Associated with Epilepsy, Colobomas,
- Dysmorphism, Developmental Delay, Intellectual Disability, and Cerebellar Hypoplasia. Am J Hum
  Genet, 2019. 105(3): p. 672-674.
- [27]. Schoch, K., et al., A Recurrent De Novo Variant in NACC1 Causes a Syndrome Characterized by
- Infantile Epilepsy, Cataracts, and Profound Developmental Delay. Am J Hum Genet, 2017. 100(2): p.343-351.
- [28]. Heyne, H.O., et al., De novo variants in neurodevelopmental disorders with epilepsy. Nat Genet,
  2018. 50(7): p. 1048-1053.
- [29]. Goos, J., et al., A de novo substitution in BCL11B leads to loss of interaction with transcriptional
  complexes and craniosynostosis. Hum Mol Genet, 2019. 28(15): p. 2501-2513.
- [30]. Ehmke, N., et al., De Novo Mutations in SLC25A24 Cause a Craniosynostosis Syndrome with
- Hypertrichosis, Progeroid Appearance, and Mitochondrial Dysfunction. Am J Hum Genet, 2017. 101(5):
  p. 833-843.
- [31]. Timberlake, A.T., et al., De novo mutations in inhibitors of Wnt, BMP, and Ras/ERK signaling
- pathways in non-syndromic midline craniosynostosis. Proc Natl Acad Sci U S A, 2017. 114(35): p.
  E7341-E7347.
- [32].Awadalla, P., et al., Direct measure of the de novo mutation rate in autism and schizophrenia cohorts.
  Am J Hum Genet, 2010. 87(3): p. 316-24.
- [33]. O'Roak, B.J., et al., Recurrent de novo mutations implicate novel genes underlying simplex autism
  risk. Nat Commun, 2014. 5: p. 5595.
- 691 [34]. O'Roak, B.J., et al., Exome sequencing in sporadic autism spectrum disorders identifies severe de
  692 novo mutations. Nat Genet, 2011. 43(6): p. 585-9.
- [35]. Uddin, M., et al., Brain-expressed exons under purifying selection are enriched for de novo
  mutations in autism spectrum disorder. Nat Genet, 2014. 46(7): p. 742-7.
- [36].Iossifov, I., et al., The contribution of de novo coding mutations to autism spectrum disorder. Nature,
  2014. 515(7526): p. 216-21.
- [37]. Neale, B.M., et al., Patterns and rates of exonic de novo mutations in autism spectrum disorders.
- 698 Nature, 2012. 485(7397): p. 242-5.
- [38]. O'Roak, B.J., et al., Sporadic autism exomes reveal a highly interconnected protein network of de
- 700 novo mutations. Nature, 2012. 485(7397): p. 246-50.

- [39]. Sanders, S.J., et al., De novo mutations revealed by whole-exome sequencing are strongly
  associated with autism. Nature, 2012. 485(7397): p. 237-41.
- 703 [40]. Sanders, S.J., et al., Multiple recurrent de novo CNVs, including duplications of the 7q11.23
- Williams syndrome region, are strongly associated with autism. Neuron, 2011. 70(5): p. 863-85.
- [41]. Luo, T., et al., De novo mutations in folate-related genes associated with common developmental
- disorders. Comput Struct Biotechnol J, 2021. 19: p. 1414-1422.
- 707 [42]. Watkins, W.S., et al., De novo and recessive forms of congenital heart disease have distinct genetic
  708 and phenotypic landscapes. Nat Commun, 2019. 10(1): p. 4722.
- [43]. Jin, S.C., et al., Contribution of rare inherited and de novo variants in 2,871 congenital heart disease
  probands. Nat Genet, 2017. 49(11): p. 1593-1601.
- 711 [44]. Sifrim, A., et al., Distinct genetic architectures for syndromic and nonsyndromic congenital heart
- defects identified by exome sequencing. Nat Genet, 2016. 48(9): p. 1060-5.
- [45]. Homsy, J., et al., De novo mutations in congenital heart disease with neurodevelopmental and other
  congenital anomalies. Science, 2015. 350(6265): p. 1262-6.
- [46]. Zaidi, S., et al., De novo mutations in histone-modifying genes in congenital heart disease. Nature,
  2013. 498(7453): p. 220-3.
- [47]. García-García, A. and I. Martin, Extracellular Matrices to Modulate the Innate Immune Responseand Enhance Bone Healing. Front Immunol, 2019. 10: p. 2256.
- [48]. Wang, J., et al., Spatial-Temporal Patterns and Inflammatory Factors of Bone Matrix Remodeling.
  Stem Cells Int, 2021. 2021: p. 4307961.
- [49]. Ajibade, A.A., H.Y. Wang and R.F. Wang, Cell type-specific function of TAK1 in innate immune
   signaling. Trends Immunol, 2013. 34(7): p. 307-16.
- [50]. Guo, Y.F., et al., The role of autophagy in bone homeostasis. J Cell Physiol, 2021. 236(6): p. 41524173.
- [51]. Montaseri, A., et al., The Role of Autophagy in Osteoclast Differentiation and Bone ResorptionFunction. Biomolecules, 2020. 10(10).
- [52]. Yang, G., et al., Are Children Suffering From Congenital Pseudarthrosis of the Tibia Associated
  With Decreased Bone Strength? Front Pediatr, 2022. 10: p. 859580.
- [53]. Li, Z., et al., Differential expression and effect analysis of lncRNA-mRNA in congenital
  pseudarthrosis of the tibia. Front Genet, 2023. 14: p. 1094298.
- [54]. Tan, Q., et al., The neurofibromatosis type I gene promotes autophagy via mTORC1 signalling
- pathway to enhance new bone formation after fracture. J Cell Mol Med, 2020. 24(19): p. 11524-11534.
- [55]. Wang, F.S., et al., Biophysical Modulation of the Mitochondrial Metabolism and Redox in Bone
  Homeostasis and Osteoporosis: How Biophysics Converts into Bioenergetics. Antioxidants (Basel),
- 735 2021. 10(9).
- [56]. Kim, J.M., et al., Osteoblast-Osteoclast Communication and Bone Homeostasis. Cells, 2020. 9(9).
- [57]. Delgado-Calle, J. and T. Bellido, The osteocyte as a signaling cell. Physiol Rev, 2022. 102(1): p.
  379-410.
- [58]. Peng, Y., et al., Type H blood vessels in bone modeling and remodeling. Theranostics, 2020. 10(1):
  p. 426-436.
- [59]. Tuckermann, J. and R.H. Adams, The endothelium-bone axis in development, homeostasis and
- bone and joint disease. Nat Rev Rheumatol, 2021. 17(10): p. 608-620.
- 743 [60]. Stucker, S., et al., Bone Angiogenesis and Vascular Niche Remodeling in Stress, Aging, and
- 744 Diseases. Front Cell Dev Biol, 2020. 8: p. 602269.

- [61]. Diomede, F., et al., Functional Relationship between Osteogenesis and Angiogenesis in Tissue
- 746 Regeneration. Int J Mol Sci, 2020. 21(9).
- [62]. Kim, H.D., et al., Biomimetic whitlockite inorganic nanoparticles-mediated in situ remodeling and
- rapid bone regeneration. Biomaterials, 2017. 112: p. 31-43.
- [63]. Zhang, R., et al., Unique roles of phosphorus in endochondral bone formation and osteocyte
  maturation. J Bone Miner Res, 2011. 26(5): p. 1047-56.
- [64]. Fischer, V. and M. Haffner-Luntzer, Interaction between bone and immune cells: Implications for
   postmenopausal osteoporosis. Semin Cell Dev Biol, 2022. 123: p. 14-21.
- [65]. Goltzman, D. and G.N. Hendy, The calcium-sensing receptor in bone--mechanistic and therapeutic
  insights. Nat Rev Endocrinol, 2015. 11(5): p. 298-307.
- [66]. Qin, L., et al., Molecular mechanosensors in osteocytes. Bone Res, 2020. 8: p. 23.
- [67]. Anderson, P.H., Vitamin D Activity and Metabolism in Bone. Curr Osteoporos Rep, 2017. 15(5):
  p. 443-449.
- [68]. Nakamichi, Y., et al., Mechanisms involved in bone resorption regulated by vitamin D. J Steroid
  Biochem Mol Biol, 2018. 177: p. 70-76.
- [69]. Zuo, H. and Y. Wan, Nuclear Receptors in Skeletal Homeostasis. Curr Top Dev Biol, 2017. 125: p.
  71-107.
- [70]. Kim, H.J., et al., Phospholipase D2 controls bone homeostasis by modulating M-CSF-dependent
   osteoclastic cell migration and microtubule stability. Exp Mol Med, 2022. 54(8): p. 1146-1155.
- [71]. Vykhovanets, E.P., et al., Concentration of several osteotropic growth factors, markers of
  osteogenesis and biologically active molecules in the blood serum of patients with congenital
  pseudarthrosis of tibia during orthopaedic treatment with combined technologies. Biomeditsinskaya
  Khimiya, 2018. 64(6): p. 525-533.
- [72]. Heervä, E., et al., Osteoclasts in neurofibromatosis type 1 display enhanced resorption capacity,
  aberrant morphology, and resistance to serum deprivation. Bone, 2010. 47(3): p. 583-90.
- [73]. Stevenson, D.A., et al., Bone resorption in syndromes of the Ras/MAPK pathway. Clin Genet, 2011.
  80(6): p. 566-73.
- [74]. Sharma, R., et al., Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in
  neurofibromin-deficient mice. Hum Mol Genet, 2013. 22(23): p. 4818-28.
- [75]. Nedeva, I.R., et al., Role of OSCAR Signaling in Osteoclastogenesis and Bone Disease. Front Cell
  Dev Biol, 2021. 9: p. 641162.
- [76]. Park, D.R., et al., Osteoclast-associated receptor blockade prevents articular cartilage destruction
  via chondrocyte apoptosis regulation. Nature Communications, 2020. 11(1): p. 4343.
- [77]. Place, D.E., et al., Osteoclast fusion and bone loss are restricted by interferon inducible guanylate
  binding proteins. Nature Communications, 2021. 12(1): p. 496.
- [78]. Chen, X., et al., LY3023414 inhibits both osteogenesis and osteoclastogenesis through the
  PI3K/Akt/GSK3 signalling pathway. Bone Joint Res, 2021. 10(4): p. 237-249.
- 782 [79]. Liu, P., et al., Effects of Mechanical Stress Stimulation on Function and Expression Mechanism of
- 783 Osteoblasts. Front Bioeng Biotechnol, 2022. 10: p. 830722.
- [80]. Wang, J., Y.X. Sun and J. Li, The role of mechanosensor Piezo1 in bone homeostasis andmechanobiology. Dev Biol, 2023. 493: p. 80-88.
- [81]. Ma, Q., et al., Significance of mechanical loading in bone fracture healing, bone regeneration, and
- 787 vascularization. J Tissue Eng, 2023. 14: p. 20417314231172573.
- [82]. Zhou, H., et al., Research progress on the hedgehog signalling pathway in regulating bone formation

- 789 and homeostasis. Cell Prolif, 2022. 55(1): p. e13162.
- [83]. Wang, H., et al., Hedgehog signaling orchestrates cartilage-to-bone transition independently of
- 791 Smoothened. Matrix Biol, 2022. 110: p. 76-90.
- [84]. Hwang, S.H., et al., The G protein-coupled receptor Gpr161 regulates forelimb formation, limb
- patterning and skeletal morphogenesis in a primary cilium-dependent manner. Development, 2018.145(1).
- [85]. Cai, W., Y. Su and G. Nan, Novel method for the treatment of congenital pseudarthrosis of the tibia
  using the gastrocnemius flap: A preliminary study. J Child Orthop, 2022. 16(3): p. 167-173.
- 797 [86]. Siebert, M.J. and C.A. Makarewich, Anterolateral Tibial Bowing and Congenital Pseudoarthrosis
- of the Tibia: Current Concept Review and Future Directions. Curr Rev Musculoskelet Med, 2022.
  15(6): p. 438-446.
- 800 [87]. Friedman, J.M., Epidemiology of neurofibromatosis type 1. Am J Med Genet, 1999. 89(1): p. 1-6.
- [88]. Schindeler, A. and D.G. Little, Recent insights into bone development, homeostasis, and repair in
  type 1 neurofibromatosis (NF1). Bone, 2008. 42(4): p. 616-622.
- 803 [89]. Banchhor, H. and V. Chimurkar, Congenital Pseudoarthrosis of the Tibia: A Narrative Review.
  804 Cureus, 2022. 14(12): p. e32501.
- 805 [90]. Ru, J.Y. and Y.F. Wang, Osteocyte apoptosis: the roles and key molecular mechanisms in 806 resorption-related bone diseases. Cell Death Dis, 2020. 11(10): p. 846.
- [91]. Wang, S., et al., The Role of Autophagy and Mitophagy in Bone Metabolic Disorders. International
  Journal of Biological Sciences, 2020. 16(14): p. 2675-2691.
- 809 [92]. Tang, A.D., et al., Full-length transcript characterization of SF3B1 mutation in chronic lymphocytic
- 810 leukemia reveals downregulation of retained introns. Nature Communications, 2020. 11(1): p. 1438.
- [93]. Haas, B.J., et al., De novo transcript sequence reconstruction from RNA-seq using the Trinity
  platform for reference generation and analysis. Nature Protocols, 2013. 8(8): p. 1494-1512.
- [94]. Zhou, Y., et al., Metascape provides a biologist-oriented resource for the analysis of systems-level
- datasets. Nat Commun, 2019. 10(1): p. 1523.
- 815 [95]. Chen, Y., et al., SOAPnuke: a MapReduce acceleration-supported software for integrated quality
- control and preprocessing of high-throughput sequencing data. Gigascience, 2018. 7(1): p. 1-6.
- 817 [96]. Li, H. and R. Durbin, Fast and accurate short read alignment with Burrows-Wheeler transform.
- 818 Bioinformatics, 2009. 25(14): p. 1754-60.
- 819 [97]. McKenna, A., et al., The Genome Analysis Toolkit: a MapReduce framework for analyzing next-
- 820 generation DNA sequencing data. Genome Res, 2010. 20(9): p. 1297-303.
- [98]. McLaren, W., et al., The Ensembl Variant Effect Predictor. Genome Biol, 2016. 17(1): p. 122.
- 822 [99]. Zhan, X., et al., RVTESTS: an efficient and comprehensive tool for rare variant association analysis
- using sequence data. Bioinformatics, 2016. 32(9): p. 1423-1426.

824







hsa04380: Osteoclast differentiation hsa05152: Tuberculosis hsa05418: Fluid shear stress and atherosclerosis hsa05204: Chemical carcinogenesis - DNA adducts hsa04010: MAPK signaling pathway hsa04020: Calcium signaling pathway hsa04151: PI3K-Akt signaling pathway hsa00280: Valine, leucine and isoleucine degradation hsa04750: Inflammatory mediator regulation of TRP channels



**MA plot** 



logCounts

#### Volcano plot



logFC

